Stay updated on Pomalidomide Combo with Pembrolizumab in rrMM Clinical Trial

Sign up to get notified when there's something new on the Pomalidomide Combo with Pembrolizumab in rrMM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pomalidomide Combo with Pembrolizumab in rrMM Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:04:51.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error with minimal HTML markup, replacing the expected study content. This indicates access to the page is blocked rather than a change to the study data.
    Difference
    19%
    Check dated 2026-09-19T20:49:27.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The term 'Multiple myeloma' and the 'related topics: MedlinePlus Genetics' section have been removed. This changes how the page references the condition and navigates to related information.
    Difference
    0.2%
    Check dated 2026-09-12T19:36:16.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The page now includes related topics: 'Multiple myeloma' and 'MedlinePlus Genetics'. These additions improve cross-referencing to disease and genetics resources, aiding discoverability without changing the core study information.
    Difference
    0.2%
    Check dated 2026-09-05T20:37:01.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    Added 2015 ( U.S. NIH Grant/Contract ) to the study identifiers and updated the page revision from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T20:02:28.000Z thumbnail image
  8. Check
    56 days ago
    Change Detected
    Summary
    The page no longer displays the primary condition label 'Multiple myeloma' and omits the related topics and Genetics resource links. This changes how the study content is presented and where users can navigate for additional information.
    Difference
    0.2%
    Check dated 2026-08-15T20:41:25.000Z thumbnail image

Stay in the know with updates to Pomalidomide Combo with Pembrolizumab in rrMM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pomalidomide Combo with Pembrolizumab in rrMM Clinical Trial page.